Tauriga Sciences Enters Retail Marketplace of India Through Successful Listing of Its Tauri-Gum Product Line on IndiaMART
May 26 2020 - 11:05AM
InvestorsHub NewsWire
India Represents One of the Fastest Growing Global Markets for CBD
Edibles and a Compelling Long-Term Opportunity for the Company
NEW YORK, NY -- May 26, 2020 -- InvestorsHub NewsWire -- Tauriga
Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences Company, with proprietary CBD & CBG infused
chewing gums and edibles product(s) as well as two ongoing
Biotechnology initiatives, today announced that it has entered the
fast growing CBD retail marketplace of India. After
several months of preparatory work, the Company has successfully
listed the entirety of its Tauri-Gum™ product line with India’s
leading E-Commerce Company (B2B, B2C, Customer to Customer),
IndiaMART InterMESH Ltd. (“IndiaMART” or
“IndiaMART.com”). The Company is selling each blister
pack of its CBD infused Tauri-Gum™ (Mint, Blood Orange, and
Pomegranate flavors) for 1,200 INR and each blister pack of its CBG
infused Tauri-Gum™ (Peach-Lemon flavor) for 1,650 INR.
INR (Currency Code): Indian Rupee
India represents one the world’s fastest growing retail market
opportunities for CBD edibles products. CBD products
extracted from Hemp are legal to buy in India. These
products must have low THC content (less than 0.3% dry
weight). Additionally, it is legal to ship CBD products
directly to a customer’s door, anywhere in India.
IndiaMART (IndiaMART.com) is India’s largest online marketplace
that assists manufacturers, suppliers & exporters to trade with
each other at a common, reliable portal. IndiaMART is
headquartered in Noida, Uttar
Pradesh, Indiaand
over the last 10 years, has become the largest Indian E-Commerce
platform for businesses with about 60% market share.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates to
the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March
18, 2020, the Company announced that it filed a provisional U.S.
patent application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration
agreement with Aegea Biotechnologies Inc. for the co-development of
a rapid, multiplexed, Novel Coronavirus (COVID-19) test with
superior sensitivity and selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full time E-Commerce fulfillment center located in
LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as
defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024